Enhanced dissolution and bioavailability of gliclazide using solid dispersion techniques by Shavi, Gopal Venkatesh et al.
International Journal of Drug Delivery 2 (2010) 49-57 
http://www.arjournals.org/ijdd.html 
 
 Research article  ISSN: 0975-0215 
 
Enhanced dissolution and bioavailability of gliclazide using solid 
dispersion techniques 
Gopal Venkatesh Shavi1, Averineni Ranjith Kumar*1, Yogendra Nayak Usha1, Karthik 





A. Ranjith Kumar 
1Department of Pharmaceu-
tics 
Manipal College of Pharma- 
ceutical Sciences 
Manipal University, Manipal 
- 576104 
Tel: +91 820 2922482 




2Department of Dental 
Materials, Manipal College 













Gliclazide is practically insoluble in water and its bioavailability is limited by 
dissolution rate. To enhance the dissolution rate and bioavailability the 
present study was aimed to formulate solid dispersions using different water 
soluble polymers such as polyethylene glycol 4000 (PEG 4000), polyethylene 
glycol 6000 (PEG 6000) using fusion method and polyvinyl pyrrolidone K- 
30 (PVP K 30) by solvent evaporation method. The interaction of gliclazide 
with the hydrophilic polymers was studied by Differential Scanning 
Calorimetry (DSC), Fourier Transformation-Infrared Spectroscopy (FTIR) 
and X-Ray diffraction analysis. Solid dispersions were characterized for 
physicochemical properties like drug content, surface morphology and 
dissolution studies. Various factors like type of polymer and ratio of the drug 
to polymer on the solubility and dissolution rate of the drug were also 
evaluated. Pharmacokinetic studies of optimized formulation were compared 
with pure drug and marketed formulation in wistar rats. The dissolution of the 
pure drug and solid dispersion prepared with PVP K 30 (1:1) showed 38.3 + 
4.5 % and 95 + 5.2 % release respectively within 30 min. Peak plasma 
concentration of pure drug, solid dispersion (PVP K 30) and marketed 
formulation was found to be 8.76 + 2.5, 16.04 + 5.5 and 9.24 + 3.6 μg/ml 
respectively, from these results it was observed that there is two fold increase 
in peak plasma concentration compared to pure drug.  Solid dispersion is an 
effective technique in increasing solubility, dissolution rate and 
bioavailability of the poorly soluble drugs. 
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Introduction  
Gliclazide (1-(3-azabicyclo-[3, 3, 0]-Oct-3-yl)-3-(p-
tolyl sulfonyl) urea) is an oral potent hypoglycemic 
second generation sulfonyl urea drug which is used for 
a long-term treatment of non-insulin dependent 
diabetes mellitus (NIDDM). It causes hypoglycemia by  
 
stimulating release of insulin from pancreatic β cells 
and by increasing the sensitivity of peripheral tissue to 
insulin. Previous studies showed that gliclazide 
possesses good general tolerability, low incidence of 
hypoglycemia and low rate of secondary failure. 
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Gliclazide is insoluble in water and has low dissolution 
rate [1]. For an oral hypoglycemic drug to be effective, 
rapid absorption from the gastrointestinal tract is 
required. However, the absorption rate of gliclazide 
from the gastrointestinal tract is slow and varied among 
the subjects. 
Gliclazide is insoluble in water which leads to poor 
dissolution rate and subsequent decrease in its 
gastrointestinal (GI) absorption [2]. Results of several 
investigations revealed that the absorption of gliclazide 
was limited by its dissolution rate. The formation of 
amorphous forms to increase drug solubility and the 
reduction of particle size to expand surface area for 
dissolution and decrease the interfacial tension with the 
aid of a water-soluble carrier are among the possible 
mechanisms for increasing dissolution rates there by 
improving bioavailability of poor water-soluble drugs. 
Various techniques for the improvement of the 
dissolution rate of poorly water-soluble drugs include 
micronization, inclusion complexes with cyclodextrin, 
amorphous drug, and solid dispersions with 
hydrophilic carriers [3]. Hence the present study was 
aimed to improve the solubility and/or dissolution rate 
of poorly water-soluble drug through the solid 
dispersion approach. 
The most commonly used hydrophilic carriers for solid 
dispersions include PEG, PVP, colloidal silicon 
dioxide, and lipids, such as polyglycolized glycerides 
(Gelucire) [4]. The solvent evaporation, melt 
adsorption, fusion, spray drying, spray freezing, spray 
congealing, melt extrusion, and supercritical fluid 
precipitation are the techniques reported for the 
preparation of solid dispersions. There is report on 
improvement of solubility of gliclazide using 
cyclodextrin inclusion complex approach [5]. In the 
present work, fusion and solvent evaporation 
techniques were used to prepare gliclazide solid 
dispersions. Hydrophilic carriers like PEG 4000, PEG 
6000 and PVP K 30 are used to prepare solid 
dispersions of gliclazide with different ratios of drug to 
carrier.  The pure drug (PD) and Solid Dispersion (SD) 
were subjected to DSC, IR and X- Ray Diffraction 
(XRD) spectroscopic studies to elucidate possible 
crystal changes in gliclazide and drug-carrier 
interactions. The optimized solid dispersion was 
selected for the further assessment of its 
pharmacokinetic evaluation.  
 
Materials and Methods   
Materials 
Gliclazide was obtained as gift sample from Lupin 
Research Park, Pune, India. Polyethylene Glycol (PEG) 
4000, PEG 6000 and Polyvinyl Pyrrolidone (PVP) K 
30 were purchased from BASF Corporation, Germany. 
All other materials and solvents used in this study were 
either pharmaceutical or analytical grade.  
 
Methods 
Preparation of the Solid Dispersions (SD) 
Solid dispersions (SD) containing gliclazide were 
prepared in different weight ratios, such as 1:1, 1: 1.5 
and 1:2 w/w for PEG 4000 (SD-1, SD-2 and SD-3) and 
PEG 6000 (SD-4, SD-5 and SD-6) respectively by 
using  fusion method. The SD of PVP K30 were 
prepared in the weight ratios of 1:0.5, 1:0.75, 1:1 w/w 
for  (SD-7, SD-8 and SD-9)  by solvent evaporation 
method as described below, and the resulting samples 
were stored in tightly closed containers until use. 
  
Fusion Method 
Solid dispersions (SD) were prepared by melting the 
accurately weighed amounts of PEG (PEG 4000 or 
PEG 6000) in a water bath and the drug was dispersed 
in the molten solution [6, 7]. The mixtures were stirred 
repeatedly, after 10 min cooled either at room 
temperature or by placing the closed container for 15 
min in an ice bath. Solid mass obtained was passed 
through the # 80 and stored in vacuum desiccator until 
use.  
 
Solvent Evaporation Method 
The solid dispersions were prepared by dissolving the 
mixture of gliclazide and the PVP K 30 at the weight 
ratios of 1:0.5, 1:0.75 and 1:1 w/w, with the aid of a 
minimal volume of mixture of methanol and acetone 
solvent system (1:1 v/v) [8]. The solvent was removed 
by evaporation under reduced pressure at 37oC   
(Osworld Vacuum oven, JRIC-8, Mumbai, India). 
Solid mass obtained was passed through the # 80 and 
stored in vacuum desiccator until use. 
 
Physicochemical Characterization  
Solubility Measurements  
The saturation solubility of drug and SD with PEG 
4000, PEG 6000 (1:1, 1: 1.5 and 1:2 w/w)  and  PVP K  
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30 (1:0.5, 1:0.75 and 1:1w/w) in distilled water and 
phosphate buffer saline (PBS pH 7.4) was determined 
by adding an excess of drug and SD to 10 ml distilled 
water or PBS in glass stoppered tubes. The stoppered 
tubes were rotated for 24 h in water bath shaker at 
37oC. The saturated solutions were filtered through a 
0.45 µm membrane filter, suitably diluted with water 
and analyzed by UV spectrophotometer, UV-1601PC, 
Shimadzu, Japan, [9]. 
 
Drug Content 
Drug content was determined by dissolving 50 mg of 
solid dispersion in solvent mixture of methanol and 
acetone (1:1 v/v), suitably diluted with pH 7.4 
phosphate buffer, filtered through 0.45 µm membrane 
filters and analyzed by UV spectrophotometer at 226 
nm. 
 
Solid State Characterization 
The DSC study was carried out using DSC-60 
(Shimadzu, Tokyo, Japan). The instrument comprises 
of calorimeter (DSC 60), flow controller (FCL 60), 
thermal analyzer (TA 60) and operating software (TA 
60). The samples (drug alone and SD-9) were heated in 
sealed aluminum pans under nitrogen flow (30 ml/min) 
at a scanning rate of 5°C/min from 25 to 250°C. Empty 
aluminum pan was used as a reference [10]. The heat 
flow as a function of temperature was measured for the 
samples. 
FTIR spectroscopy study was conducted using a 
Shimadzu FTIR 8300 Spectrophotometer (Shimadzu, 
Tokyo, Japan) and the spectrum was recorded in the 
wavelength region of 4000 to 400 cm-1. The procedure 
consisted of dispersing a sample (drug alone and SD-9) 
in KBr and compressing into discs by applying a 
pressure of 5 tons for 5 min in a hydraulic press. The 
pellet was placed in the light path and the spectrum was 
obtained. 
X-ray diffraction patterns of the samples (drug and SD-
9) were obtained using D8 X-ray powder 
diffractometer (Bruker AXS, Germany) equipped with 
D8 TOOLS software, a theta compensating slit and a 
silicon detector [11].  The scans were recorded from 2 
to 50o, with a step size of 0.03o, 2θ and a count time of 
0.5 sec at 25oC using copper radiation. 
 
Shape and Surface Morphology 
The shape and surface morphology of the solid 
dispersion was studied by scanning electron 
microscopy (SEM), JEOL, JSM 50A, Tokyo, Japan. 
The samples were mounted on double-sided adhesive 
tape that has previously been secured on copper stubs 
and then analyzed. The accelerating voltage was 5 kV.  
 
Dissolution Studies 
The dissolution rate of pure gliclazide and solid 
dispersion systems were studied using the basket 
method (USP Type-II) at 37°C in 900 ml of 0.1N HCL 
(pH 1.2) at 100 rpm [12]. Samples equivalent to 10 mg 
of gliclazide were subjected to the testing. Five 
milliliter samples of dissolution medium were 
withdrawn and filtered at different time intervals for 
analysis of the drug content at 226 nm using UV 
Spectrophotometer. At each time of withdrawal, 5 ml 




After determining the drug content and release studies, 
the optimized formulation was charged for the 
accelerated stability studies according to ICH 
guidelines (40 ± 2ºC and 75 ± 5% RH) for a period of 3 
months in a stability chamber (Thermolab, Mumbai, 
India). The optimized formulations were placed in USP 
type-I flint vials and hermetically closed with 
bromobutyl rubber plugs and sealed with aluminum 
caps. The samples were withdrawn at 15, 30, 60 and 90 




The preclinical studies were carried out in healthy 
Wistar rats (weighing about 200-250g), obtained from 
central house, Manipal University, Manipal. They were 
housed in elevated wire cages with free access to food 
(Lipton feed, Mumbai, India) and water. The 
preclinical study protocol was approved by Institutional 
Animal Ethical Committee, Kasturba Medical College, 
Manipal. The overnight fasted male wistar rats were 
divided into three different groups (n=6); group I  was 
administered  with pure gliclazide and group II  with 
solid dispersion (SD-9) and group III with marketed 
formulation (Reclide® Tablets, Dr.Reddy’s 
Laboratories, Baddi, India). All three groups were 
administered through oral route (0.5% sodium CMC 
suspension) at the dose of 8.3 mg/kg.  
Then blood samples were collected at predetermined 
intervals of 0.5, 1, 2, 4, 6, 8, and 12 h of post-dose into 
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heparinized tubes from orbital sinus. The plasma was 
separated immediately using cold centrifugation (Remi 
Equipments Ltd., Mumbai, India) at 10000 rpm for 5 
min and the plasma was stored at -30 o C until analysis. 
 
Bio Analysis of Gliclazide in Rat Plasma  
Chromatographic Condition  
Water alliance 2695-separation module with waters 
2487 dual UV detector was used. Millennium software 
version 4.0 s used for data acquisition. Inertsil ODS (25 
cm × 4.6 mm, 5 μ) column was used as a stationary 
phase. Mobile phase comprised of acetonitrile and 0.02 
M ammonium acetate buffer, pH 4.5 (60:40 v/v) at the 
flow rate of 1 ml/min. Injection volume was 50 µl and 
run time is 12 min, column was maintained at ambient 
temperature and the eluent was detected at 228 nm. 
 
Extraction Procedure 
The extraction of gliclazide in rat plasma was carried 
out by simple protein precipitation method, using 
methanol as an extracting solvent. Briefly 100 µL of  
rat plasma sample was taken  in the 1.5 ml eppendorff  
tubes  and  mixed with 10 μL of Glimepiride (Internal 
Standard) working stock solution (100 μg/ml) and 
vortexed for 1 min. Then 250 µL of methanol was 
added and vortexed for 4 min and centrifuged at 10000 
rpm for 5 min. The clear supernatant 50 µL was 
subjected for HPLC analysis. 
 
Statistical Analysis 
The data were analysed for statistical significance 
using SPSS 11.5 for windows software by One-Way 
ANOVA followed by Post-hoc (Dunnett’s) test at 
p<0.05. The results were considered as significant if p 
less than 0.05. 
 
Results 
Solubility Studies and Drug Content 
The results of saturation solubility studies are given in 
Table 1. The solubility of pure drug in water and in 
PBS (pH 7.4) was found to be 27.04 ± 0.56 and 57.06 ± 
0.67 µg/ml. The solubility of SD using PEG 4000 
(1:2), PEG 6000 (1:2) and PVP K30 (1:1) in water was 
found to be 57.79 ± 1.35, 58.92 ± 1.46, 60.24 ± 1.75 
µg/ml and in PBS (pH 7.4) 81.89 ± 1.35, 83.42 ± 1.76 
and 86.24 ± 1.63 µg/ml respectively. The drug content 
of solid dispersion with PEG 4000, PEG 6000 and PVP 
K 30 was found to be in the range of 95 ± 1.45 to 98 ± 
2.36%. 
 
Table 1: Solubility studies of drug and solid 
dispersions 
 
Solubility (µg/ml) Samples 
Water PBS 
Pure drug 27.04 + 0.56 57.06 + 0.67 
SD-1 35.59 + 1.12 63.78 + 1.19 
SD-2 46.87 + 1.24 72.76 + 1.21 
SD-3 57.79 + 1.35 81.89 + 2.35 
SD-4 36.22 + 1.05 65.12 + 1.13 
SD-5 48.86 + 1.87 73.52 + 1.15 
SD-6 58.92 + 1.46 83.42 + 1.76 
SD-7 38.23 + 1.45 56.24 + 1.43 
SD-8 52.24 + 1.52 71.24 + 1.25 
SD-9 60.24 + 1.75 86.24 + 1.63 
 
Solid State Characterization 
The solid state characterization of drug and SD were 
investigated using IR, DSC to study the compatibility 
with carriers and XRD to find out crystallinity nature 
of gliclazide and SD [13].  The DSC thermograms of 
gliclazide, PVP K30 and SD are shown in Figure 1. 
The sharp melting endotherm of pure gliclazide 
appeared at 168.9oC, whereas small endotherm was 
observed in solid dispersions at 160.0oC prepared with 
PVP K30, indicated the decreased intensity of 
crystalline nature [14]. It may be due to that the drug 
molecules were dispersed in the PVP. Thermal 
property of solid dispersion (SD9) was changed 
compared to other solid dispersions. Solid dispersions 
of polyethylene glycol showed slight decrease in 
melting point of the gliclazide compared to that of pure 
drug. This may be speculated that gliclazide was 
dissolving in PEG 4000 and 6000.   
The IR spectrum of the solid dispersion was compared 
with that of the pure drug as given in Figure 3. It can be  
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clearly seen from the spectra, gliclazide was 
characterized by the absorption of carbonyl (C=O) 
sulphonyl urea group at 1708.99 cm−1, NH group at 
3275.24 cm−1 and sulphonyl group at 1348.29 and 
1166.04 cm−1.  All peaks were observed in solid 




Figure 1. DSC thermograms of pure Gliclazide, 
PVP K30 and solid dispersion (SD-9) 
 
The crystallinity of pure gliclazide and SD-9 were 
examined using X-ray diffraction and profiles are 
depicted in Figure 3.  
 
 
Figure 2. Infra red spectrum of (a) Pure Gliclazide 
(b) Solid dispersion (SD-9)  
The diffraction spectra of gliclazide showed numerous 
distinct peaks indicating presence of high crystalline 
state. From the X-Ray diffraction profile, the 
characteristic gliclazide peaks with high intensity were 
found to be at 8.45, 8.95 (doublet), 7.30, 7.45 and 6.53, 
6.25 at two theta degrees. The XRD pattern of solid 
dispersion of sample SD-9 exhibited all the 
characteristic diffraction peaks of gliclazide, with 
lower intensity. This study revealed that the 
crystallinity was reduced to a certain extent in the solid 
dispersion form. The reduction in crystallinity appears 
in solid dispersions was independent of the method 
used. XRD profiles of the SD-9 also lacked some of the 
diffraction peaks associated with gliclazide implying 
the amorphous nature of gliclazide. 
 
 
Figure 3. X-ray diffraction patterns of (a) Pure 
Gliclazide (b) Solid dispersion (SD-9) 
 
Shape and Surface Morphology 
The SEM results are shown in Figure 4. The surface 
morphology studies revealed that the solid dispersion 
was closely compacted into small spherical form. 
Gliclazide existed in lamellar-like crystals, consisted of 
large crystalline particles of rather irregular size. On 
the contrary, the solid dispersions appeared in the form 
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Pharmacokinetic Study of spherical particles and the original morphology of 
components disappeared, which supported DSC and 
XRD data. These results demonstrated that gliclazide in 
solid dispersion was homogeneously dispersed into 
PVP K30 at the molecular level. 
The results of pharmacokinetic study were showed in 
Table 3. The rat plasma concentration- time profiles 
curve was shown in the Figure 6. The solid dispersion 
(SD-9) of gliclazide formulation had increased the 
systemic exposure (AUC (0-∞)) significantly (P< 0.05) 
compared to the free drug and marketed formulation. 
The peak plasma concentration (Cmax) of free drug, SD-
9 and marketed formulation was found to be 8.76 + 2.5, 
16.04 + 5.5 and 9.24 + 3.6 respectively. There was no 
significant difference in biological half life (t1/2) of SD-
9 to that of free drug and marketed formulation [17]. 
Solid dispersion (SD-9) had a detectable amount of 
drug in plasma up to 12 h indicating drug retained for 
longer time in the body when administered in the form 





 Figure 4. SEM images of (a) Pure Gliclazide (b) 




























 The dissolution profiles of pure gliclazide and SD with 
PVP (1:1) were as shown in Table 2 and Figure 5. The 
dissolution profile of the pure gliclazide and marketed 
tablet showed 38.3 ± 5.5% and 43.7 ± 4.6 % in 30 min 
respectively [15].  Drug release of SD with different 
ratios prepared with PEG 4000 (1:2) showed 81.6 ± 4.6 
%, PEG 6000 (1:2) showed 87.4 ± 3.7 % whereas PVP 
K 30 (1:1) showed 95 ± 3.8 % release in 30 min 
indicating better release when compared to pure drug 
and other formulations prepared with PEG 4000 and 
6000 [16].  
 
Stability Study  
The optimized formulation did not show any 
significant change in the drug content during stability 
study. The values for drug content (%) under 
accelerated stability conditions were: 0 day: 99.98 ± 
0.16; 15 days: 99.80 ± 0.32; 30 days: 98.71 ± 0.21; 60 
days: 98.30 ± 0.45; 90 days: 98.1 ± 0.27.  
Figure 5. Dissolution profile of Pure Gliclazide, 




The increase in solubility of gliclazide was observed 
using hydrophilic polymers. Between the three 
polymers used, solid dispersion of PVP K30 showed 
better effect on solubility of gliclazide compared to 
other polymers. The increase in solubility of gliclazide 
by PVP K30 probably may be due to the formation of 
soluble complexes between water-soluble polymeric 
carrier and poorly soluble drug.  
 
Bio Analysis of Gliclazide  
The HPLC method was linear over the range of 
concentration from 0.05-20 µg/mL of rat plasma with 
the correlation coefficient (r2 =0.9976). The method was 
validated as per the US FDA guidelines. The gliclazide 
peak was well separated from the endogenous 
interferences and sharp symmetric peak was observed 
in the chromatograms.  
 
 
Table 2: In vitro dissolution data for pure drug, marketed tablet and solid dispersions. 
 





















































































































































The solid state characteristics indicated decreased 
crystallinity of drug in the form of solid dispersion.  
The peak position (angle of diffraction) was an 
indication of crystal structure which peak height was 
the measure of crystallinity [19]. The diffractograms of 
pure gliclazide exhibited a series of intense peaks, 
which were indicative of its crystallinity. Intensity of 
peak sharpness was reduced in solid dispersion 
compared to pure drug. Various studies have shown 
that PVP K30 inhibits crystillanity of drugs and 
resulting in amorphous nature of drug in the solid 
dispersions. Crystallization inhibition was attributed to 
two effects: interactions, such as hydrogen bonding 
between the drug and the polymer and the entrapment 
of the drug molecules in the polymer matrix during 
solvent evaporation or a combination of both. The 
solvent was removed during the preparation of solid 
dispersions, viscosity of the system increased very 
rapidly leading to a decrease in drug mobility. When 
the solvent was evaporated completely, drug molecules 
were frozen in the polymer matrix. A crystal lattice was 
not formed, but the drug molecules were randomly 
“ordered” comparable to the liquid state and exhibited 
short-range order over only a few molecular 
dimensions. An increase in the dissolution rate of 
gliclazide has been attributed to the hydrophilic nature 
of the polymer, which increased the wettability of the 
drug and also due to decrease in its crystallinity when 
prepared as a solid dispersion, which was confirmed by 
DSC and XRD results. In presence of PVP K-30, drug 
had better wettability, hence the dissolution of drug 
was greater in the form of solid dispersion. No 
considerable changes in the drug release profile of the 
solid dispersions were observed during the accelerated 
stability studies for a period of 3 months. The 
gliclazide solid dispersion formulation had 
significantly increased systemic availability compared 
to that of free drug and marketed formulation. It might 
be due to effect of hydrophilic polymers which would 
have improved the aqueous solubility and dissolution 
rate and hence there was improved systemic exposure 
in pharmacokinetic studies. 
  




Free Drug Solid 




Cmax  (µg/mL)  8.76 + 2.5 16.04 + 5.5 9.24 + 3.6 
Tmax (1/hr)  2.1 + 0.6 2.32 + 0.4 2.25 + 0.8 
AUC(0-∞) (µg-
hr/mL) 
73.90 + 10.2 130.12 + 
15.2* 
76.86 + 9.2 
T1/2 (hr) 3.42 + 1.2 2.79 + 2.1 3.21 + 0.8 
*P< 0.05 ,95% CI 




Pilot study showed that when gliclazide was dispersed 
in a suitable water-soluble carrier such as PEG 6000 or 
PVP K 30, its dissolution was enhanced compared with 
pure drug. The water soluble carrier may operate in the 
microenvironment (diffusion layer) immediately 
surrounding the drug particles in the early stage of 
dissolution, since the carrier completely dissolves in 
short time, enhancing the solubility and dissolution of 
drug. The study clearly showed that addition of PVP 
K30 to gliclazide improved its dissolution rate. 
Mechanisms involved are solubilization and improved 
wetting of the drug in the PVP K30 rich 
microenvironment formed at the surface of drug 
crystals after dissolution rate. The crystallinity of the 
drug was reduced in solid dispersion formulation with 
polymers i.e. PVP K30. Finally it could be concluded 
that solid dispersion of glicalzide using hydrophilic 
polymers would improved the aqueous solubility, 
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